ALLUVI: A THOROUGH EXPLORATION INTO THE MEDICATION'S POTENTIAL

Alluvi, initially dubbed LY3414901, represents a noteworthy advancement in obesity management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist exhibits remarkable effectiveness in early trial data, with considerable weight lo